Real-World Impact of Maralixibat Treatment on Concomitant Medication Use in USA-Based Patients with Alagille Syndrome and Cholestatic Pruritus: A Retrospective Analysis

INTRODUCTION: Alagille syndrome (ALGS) is a rare cholestatic liver disease characterized by severe pruritus, with many patients also experiencing impaired growth, failure to thrive, and fat-soluble vitamin deficiencies. Patients often require multiple antipruritic medications to control pruritus and may also receive nutritional or vitamin supplements to address nutritional deficiencies and improve growth, leading to substantial polypharmacy burden. Maralixibat, a minimally absorbed ileal bile acid transporter inhibitor, is approved for the treatment of cholestatic pruritus in patients with ALGS ≥ 3 months of age in the USA and ≥ 2 months of age in the European Union (EU). This study evaluated real-world concomitant medication usage during long-term maralixibat treatment using pharmacy data from Mirum Access Plus, a single-source specialty pharmacy and education program for patients receiving maralixibat. METHODS: A retrospective analysis was conducted using pharmacy data from the Mirum Access Plus program to evaluate concomitant medication trends for at least 2 years of potential use. Data were extracted on April 30, 2024, and included all patients in the USA who initiated maralixibat by April 1, 2022, and had not discontinued therapy. RESULTS: This analysis included 178 patients with ALGS who received maralixibat. The median age at maralixibat initiation was 6 years. At the start of maralixibat treatment, patients were taking a median of two antipruritic medications and one nutritional or vitamin supplement. During maralixibat treatment, 43% of patients discontinued ≥ 1 concomitant medication, 21% discontinued ≥ 2 medications, and 8% discontinued ≥ 3 medications. CONCLUSIONS: These real-world results indicate treatment with maralixibat may reduce polypharmacy burden in patients with ALGS and their caregivers by enabling discontinuation of antipruritic medications and nutritional or vitamin supplements.

Authors

Publication Details

Journal
Advances in Therapy
Published
2026-11-12
DOI
https://doi.org/10.1007/s12325-026-03844-5
Primary Topic
Pediatric Hepatobiliary Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-World Impact of Maralixibat Treatment on Concomitant Medication Use in USA-Based Patients with Alagille Syndrome and Cholestatic Pruritus: A Retrospective Analysis

Jolan Terner-Rosenthal, Robin Howard, Liz Turner, Wiktor Stopka et al.
Advances in Therapy
Pediatric Hepatobiliary Diseases and Treatments
article

Real-World Impact of Maralixibat Treatment on Concomitant Medication Use in USA-Based Patients with Alagille Syndrome and Cholestatic Pruritus: A Retrospective Analysis

Jolan Terner-Rosenthal, Robin Howard, Liz Turner, Wiktor Stopka, Renee Shiota
article en

Abstract

INTRODUCTION: Alagille syndrome (ALGS) is a rare cholestatic liver disease characterized by severe pruritus, with many patients also experiencing impaired growth, failure to thrive, and fat-soluble vitamin deficiencies. Patients often require multiple antipruritic medications to control pruritus and may also receive nutritional or vitamin supplements to address nutritional deficiencies and improve growth, leading to substantial polypharmacy burden. Maralixibat, a minimally absorbed ileal bile acid transporter inhibitor, is approved for the treatment of cholestatic pruritus in patients with ALGS ≥ 3 months of age in the USA and ≥ 2 months of age in the European Union (EU). This study evaluated real-world concomitant medication usage during long-term maralixibat treatment using pharmacy data from Mirum Access Plus, a single-source specialty pharmacy and education program for patients receiving maralixibat. METHODS: A retrospective analysis was conducted using pharmacy data from the Mirum Access Plus program to evaluate concomitant medication trends for at least 2 years of potential use. Data were extracted on April 30, 2024, and included all patients in the USA who initiated maralixibat by April 1, 2022, and had not discontinued therapy. RESULTS: This analysis included 178 patients with ALGS who received maralixibat. The median age at maralixibat initiation was 6 years. At the start of maralixibat treatment, patients were taking a median of two antipruritic medications and one nutritional or vitamin supplement. During maralixibat treatment, 43% of patients discontinued ≥ 1 concomitant medication, 21% discontinued ≥ 2 medications, and 8% discontinued ≥ 3 medications. CONCLUSIONS: These real-world results indicate treatment with maralixibat may reduce polypharmacy burden in patients with ALGS and their caregivers by enabling discontinuation of antipruritic medications and nutritional or vitamin supplements.

Advances in Therapy
Good health and well-being
Pediatric Hepatobiliary Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon